Abstract Background Pseudomonas aeruginosa (PsAr) is responsible for roughly 10% of catheter-associated UTIs (CAUTIs) and up to 16% of ICU infections, often leading to complications such as bacteremia. Fluoroquinolones (FQs) remain one of the few oral treatment options for PsAr UTIs. Despite rising resistance, FQs like ciprofloxacin and levofloxacin achieve high urinary concentrations—potentially overcoming higher MICs and maintaining efficacy. In 2019, the CLSI lowered PsAr FQ breakpoints, raising questions about continued clinical effectiveness for higher MICs. This study aims to evaluate the use of FQs for treating pseudomonal UTIs and to assess clinical success in relation to MIC levels.Table 1.Baseline CharacteristicsTables 2 all recurrent cases remained susceptible to their respective fluoroquinolone. Among those with recurrence, 5 (62.5%) in the levofloxacin group and 18 (60%) in the ciprofloxacin group had indwelling catheters. No patients had a documented history of kidney stones by provider notes or imaging. Conclusion FQs remain a primary oral treatment option for pseudomonal UTIs and may achieve clinical cure despite higher MICs. Further research is needed to determine if high urinary FQ concentrations improve outcomes against intermediate or resistant PsAr isolates. Disclosures All Authors: No reported disclosures
Nicov et al. (Thu,) studied this question.